作者
David A Palma, Robert Olson, Stephen Harrow, Rohann JM Correa, Famke Schneiders, Cornelis JA Haasbeek, George B Rodrigues, Michael Lock, Brian P Yaremko, Glenn S Bauman, Belal Ahmad, Devin Schellenberg, Mitchell Liu, Stewart Gaede, Joanna Laba, Liam Mulroy, Sashendra Senthi, Alexander V Louie, Anand Swaminath, Anthony Chalmers, Andrew Warner, Ben J Slotman, Tanja D De Gruijl, Alison Allan, Suresh Senan
发表日期
2019/12
期刊
BMC cancer
卷号
19
页码范围
1-15
出版商
BioMed Central
简介
Background
Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control for primary tumors or metastases. A recent randomized phase II trial evaluated SABR in a group of patients with a small burden of oligometastatic disease (mostly with 1–3 metastatic lesions), and found that SABR was associated with benefits in progression-free survival and overall survival. The goal of this phase III trial is to assess the impact of SABR in patients with 4–10 metastatic cancer lesions.
Methods
One hundred and fifty-nine patients will be randomized in a 1:2 ratio between the control arm (consisting of standard of care palliative-intent treatments), and the SABR arm (consisting of standard of care …
学术搜索中的文章
DA Palma, R Olson, S Harrow, RJM Correa… - BMC cancer, 2019